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Abstract
Soluble N-ethylmaleimide sensitive factor attachment protein
receptors (SNAREs) are crucial for exocytosis, trafﬁcking, and
neurite outgrowth, where vesicular SNAREs are directed
toward their partner target SNAREs: synaptosomal-associated
protein of 25 kDa and syntaxin. SNARE proteins are normally
membrane bound, but can be cleaved and released by
botulinum neurotoxins. We found that botulinum proteases
types C and D can easily be transduced into endocrine cells
using DNA-transfection reagents. Following administration of
the C and D proteases into normally refractory Neuro2A
neuroblastoma cells, the SNARE proteins were cleaved with
high efﬁciency within hours. Remarkably, botulinum protease
exposures led to cytotoxicity evidenced by spectrophotometric
assays and propidium iodide penetration into the nuclei. Direct
delivery of SNARE fragments into the neuroblastoma cells
reduced viability similar to botulinum proteases’ application.
We observed synergistic cytotoxic effects of the botulinum
proteases, which may be explained by the release and
interaction of soluble SNARE fragments. We show for the
ﬁrst time that previously observed cytotoxicity of botulinum
neurotoxins/C in neurons could be achieved in cells of
neuroendocrine origin with implications for medical uses of
botulinum preparations.
Keywords: botulinum, cytotoxicity, neuro2A, SNARE, syntaxin,
transfection reagents.
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Vesicular transport, protein trafﬁcking, and exocytosis
necessitate membrane fusion of vesicles, which is catalyzed
by soluble N-ethylmaleimide sensitive factor attachment
protein receptors (SNAREs) (Bock et al. 2001; Jahn et al.
2003; Meunier et al. 2003; Bajohrs et al. 2005; Sudhof and
Rothman 2009; Mohrmann et al. 2010; Gao et al. 2012;
Risselada and Grubmuller 2012). SNAREs are divided into
two categories depending on their cellular locations: v-
SNAREs on vesicles (also known as synaptobrevins; or
vesicle-associated membrane proteins) and the t-SNAREs
located on the target membrane, the synaptosome-associated
protein of 25 kDa (SNAP25), and syntaxin (Bajohrs et al.
2005). SNAREs form a highly stable, tetrahelical coil–coil
bundle that fuses the vesicle to the target membrane
(Fig. 1a). Syntaxin and synaptobrevin each contribute one
a-helix, whereas the SNAP25 protein contributes two
(Wendler and Tooze 2001; Sudhof and Rothman 2009).
There have been over 35 different SNARE isoforms
identiﬁed, each associated with distinct organelles that
participate in the precise and scrupulous vesicle fusion
essential for proper cellular function (Bock et al. 2001;
Wendler and Tooze 2001; Koticha et al. 2002; Xu and Xu
2008).
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Botulinum neurotoxins (BoNT) have been invaluable in
the studies of SNARE proteins and exocytosis (Erbguth and
Naumann 1999; Sorensen et al. 2002). BoNTs are natively
produced by anaerobic bacteria of the genus Clostridium and
are responsible for the deadly disease called botulism
manifested by neuromuscular paralysis (Erbguth and Nau-
mann 1999; Montecucco and Molgo 2005). The BoNTs
carry selective SNARE proteases, which have highly precise
substrate recognition sites (Montecucco and Schiavo 1994;
Montal 2010). BoNTs have been utilized in many medical
and biotechnological applications (Davletov et al. 2005;
Chaddock and Marks 2006; Foster et al. 2006; Ferrari et al.
2011; Arsenault et al. 2013). A typical BoNT is expressed as
a single-chain precursor protein that is processed into two
polypeptide chains. The SNARE protease (50 kDa light
chain) located at the N terminus is linked, via a disulﬁde
bond, to the C terminal part (100 kDa heavy chain) which is
composed of the translocation domain and the receptor-
binding domain (Chaddock and Marks 2006; Binz and
Rummel 2009). Among seven commonly known BoNT
serotypes (A–G) BoNT/A, C, and E cleave SNAP25, BoNT/
B, D, F, and G cleave synaptobrevins, and BoNT/C also
cleaves syntaxin (Montecucco and Schiavo 1994; Rummel
et al. 2004; Dong et al. 2006; Antonucci et al. 2008; Binz
et al. 2010). To reach their intraneuronal substrates, BoNTs
ﬁrst bind neuronal surface gangliosides and then a synaptic
vesicle protein on the pre-synaptic membrane for subsequent
internalization (Montecucco et al. 1994; Rummel et al.
2004, 2009; Dong et al. 2006; Mahrhold et al. 2006; Binz
and Rummel 2009). Once the internalized vesicle acidiﬁes,
the translocation domain forms a putative protein transduc-
tion channel that enables translocation of the protease into
the cytosol following reduction in its disulﬁde bond
(Koriazova and Montal 2003; Puhar et al. 2004; Fischer
2013; Pirazzini et al. 2013). BoNTs are potentially lethal as
they paralyze muscles, such as the diaphragm, but are
thought to be non-cytotoxic to neurons with the clear
exception of BoNT/C and possibly BoNT/E (Williamson and
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Fig. 1 Efﬁcient transductionofbotulinumtypeCand
Dproteases intoneuroblastomacells. (a)Schematic
of thecomplexformationbysynaptobrevin,v-soluble
N-ethylmaleimide-sensitive factor attachment
protein receptor (SNARE) (green) and syntaxin/
SNAP25, t-SNAREs (red and fuchsia) necessary for
vesicle fusion with the cell membrane. The
substrates of the botulinum protease type C are
syntaxin andSNAP25,whereas the typeDprotease
cleaves only synaptobrevin. (b) Confocal image
showing syntaxin 1 (red; left), SNAP25 (red; middle),
andsynaptobrevins1-3 (green; right) inNeuro2Acells
asrevealedbyimmunocytochemistry.(c)Comparison
of the efﬁciency of different reagents used to deliver
botulinum protease type C (top panel). Cleavage of
syntaxins evidenced by the disappearance of the
immunoreactive band,whereas cleavage ofSNAP25
is evidenced by the appearance of a proteolytic
product SNAP25Δ8. SNAP25 immunoreactivity
served as a loading control. Middle panel shows the
dosedependenceofSNAREcleavage following20 h
treatment. Bottom panel shows a time course using
0.2 lg/mL of the type C protease. (d) Comparison of
different reagents used to deliver botulinum protease
type D (top panel) and efﬁcacy (lower panels) of
synaptobrevin 2 (Syb2) cleavage evidenced by the
disappearanceof the immunoreactiveband.SNAP25
was used as a loading control.
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Neale 1998; Berliocchi et al. 2005; Zhao et al. 2010; Peng
et al. 2013). The underlying causes of BoNT/C-mediated
neurotoxicity are still under investigation. BoNT/C-released
syntaxin fragment (aa 1-253) may cause cytotoxicity, but
was thought to be rapidly degraded as observed by the loss of
syntaxin immunoreactivity (Foran et al. 2003). However,
immunoreactivity is not necessarily a measure of protein
presence and other studies have been able to identify
syntaxin fragments in cell extracts (Tsukamoto et al.
2012). If these fragments are free to diffuse and to engage
SNAP25 and synaptobrevin or other non-neuronal SNAREs
(Fasshauer et al. 1999), then they may potentially interfere
with the scrupulous fusion events. Others have reported that
BoNT/C-affected neurons ﬁrst undergo axonal degeneration,
possibly because of trafﬁcking problems, followed by
apoptosis (Berliocchi et al. 2005; Zhao et al. 2010; Peng
et al. 2013).
BoNT protease-based medicines have recently been
proposed for the treatment of endocrine disorders and
therefore we investigated the possible cytotoxic effects of
SNARE cleavage in endocrine cells. We have utilized model
neuroblastoma cells (N2A) that abundantly express all three
neuronal SNARE proteins: syntaxin 1, SNAP25, and
synaptobrevin 2 (Syb2). N2A cells have been shown to be
resistant to native BoNTs because of lack of neuronal
gangliosides (Yowler et al. 2002). We thus used transfection
reagents to internalize the proteases into the cell interior as it
was shown before that polycationic lipid and polymers can
enable the endocytosis and translocation of the BoNT type
A protease as well as other peptides and proteins into cells
(Kuo et al. 2010; Oba and Tanaka 2012). We now show
that a selection of transfection reagents can mediate the
intracellular entry of the botulinum protease serotypes C and
D into neuroblastoma cells allowing investigation of botu-
linum action. Our results show that the intracellular cleavage
of syntaxin and SNAP25 by the type C protease and
synaptobrevin by the type D protease can cause severe
cytotoxic effects. The soluble SNARE fragments were able
to form ternary complexes and when transduced, triggered
loss of cell viability mimicking the type C and D protease
effects.
Materials and methods
Cell culture
Mouse Neuro2A cells (ATCC: CCL-131; LGC Standards;
Teddington, UK) were grown in a 37°C incubator at 5% CO2
in low-glucose Dulbecco’s modiﬁed eagle medium (Gibco; Paisly,
UK) supplemented with 10% fetal clone 1 calf serum (HyClone;
Fisher Scientiﬁc; Loughborough, UK) and 1% penicillin/strepto-
mycin (P/S) (Invitrogen; Paisley, UK). Every 3–4 days, cells were
washed with phosphate-buffered saline (PBS) and resuspended in
culture medium using ﬂow pressure, then counted by hemacy-
tometer. Min6 and SH-SY5Y cells were cultured as previously
described (Arsenault et al. 2013). Rat cortical neuronal cells were
isolated as previously described (Arsenault et al. 2013). Sprague–
Dawley rats of both sexes were obtained from the Medical
Research Council Laboratory of Molecular Biology’s Biological
Services Group. Experiments were approved by the Medical
Research Council Laboratory of Molecular Biology, Cambridge.
Hela cells were cultured in high-glucose Dulbecco’s modiﬁed
eagle medium with 10% fetal clone 1 calf serum and 1% P/S.
Cells were plated at 1 9 106 cells per 9 cm culture dish (BD
Biosciences; San Jose, CA, USA), at 8 9 104 cells per well in
uncoated 24-well plates (BD Biosciences) with or without cover
slips, or at 8 9 103 cells per well in uncoated 96-well plates (BD
Bioscience).
Protein and peptide synthesis
BoNT/A1 (1-872), rat SNAP25B (22-206) (all four Cys mutated to
Ala), and rat synaptobrevin 2 (25-84) were prepared as Glutathione
S-transferase (GST)-tagged proteins cleavable by thrombin and
puriﬁed as previously described (Darios et al. 2010; Ferrari et al.
2012). Syntaxin 1 (1-226) was obtained from ATgen (Bio Trend,
K€oln, Germany). The production of serotype C and D proteases was
described elsewhere (Vaidyanathan et al. 1999; Sikorra et al. 2006).
Rat synaptobrevin 2 (25-52) Ac-RLQQTQAQVDEVVDIMRVNV
DKVLERD-NH2 and syntaxin 1A (201-245) Ac-EIIKLENS
IRELHDMFMDMAMLVESQGEMIDRIEYNVEHAVDYVE-NH2
peptides were prepared as previously described (Darios et al. 2010;
Ferrari et al. 2012). Rat syntaxin 1A conjugated to Fluorescein
isothiocyanate (FITC) FITC-Ahx-EIIKLENSIRELHDMFMDMAM
LVESQGEMIDRIEYNVEHAVDYVE-NH2, rat complexin (31-59)
Ac-GGGERKAKYAKMEAEREVMRQGIRDKYGIKKG-NH2, rat
synaptobrevin 2 conjugated to FITC (31-55) sequence FITC-
Ahx-RLQQTQAQVDEVVDIMRVNVDKVLE-NH2 and penetratin
Ac-RQIKIWFQNRRMKWKK-NH2 were synthesized by Peptide
Synthetics (Southampton, UK). Protein and peptide concentration
was determined by Pierce bicinchoninic acid (BCA) protein assay
kit (Thermo-scientiﬁc; Loughborough, UK) according to manufac-
turer protocol.
Protein transduction
Transduction was performed 24 h after plating with proteins and
peptides at desired concentrations that were pre-incubated for
30 min in 100 lL of Opti-MEM (GIBCO) with 2.5 lL of
transfection reagents (per 500 lL of culture medium in a 24-well
plate). Lipofectamine (Invitrogen), Lipofectamine LTX (Invitrogen),
Transpass P (New England BioLabs; Hitchin, UK), and Fugene HD
(Promega; Southampton, UK) were used as received from manu-
facturer. Pro-Ject (Thermo Scientiﬁc) was prepared according to
manufacturer protocol. Cells were incubated with proteins and
transfection reagents at 37°C in cell culture incubator for 42 h or as
otherwise indicated.
Confocal microscopy
Cells were grown on cover slips in 24-well plates and treated
with compounds 16 h before ﬁxation. Wells were washed once
with PBS, and incubated in 4% paraformaldehyde (Alfa Aesar;
Haysham, UK) in PBS for 20 min at 22C. Wells were washed
three times with PBS for 5 min and incubated 10 min in 10 mM
NH4Cl (Sigma-Aldrich; Dorset, UK). The cells were then
© 2013 The Authors. Journal of Neurochemistry published by John Wiley & Sons Ltd on behalf of International
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incubated for 30 min in a permeabilization solution composed of
0.1% Triton X-100 (Sigma-Aldrich) and 5% Bovine serum
albumin (BSA; Sigma-Aldrich) in PBS at 22C. Permeabilization
solution was removed and replaced with 5% BSA in PBS
containing appropriate primary antibodies for 90 min at 22C.
Mouse monoclonal anti-SNAP25 (SMI81; Novagen; EMD Mil-
lipore; Feltham, UK), rabbit polyclonal anti-synaptobrevin 1/2/3
antibody (Synaptic Systems; Goettingen, Germany), and mouse
monoclonal anti-syntaxin 1 (clone HPC-1; Sigma-Aldrich), were
diluted at 1 : 500. The wells were washed three times in PBS,
then incubated for 30 min with Alexa Fluor 594 goat anti-
mouse IgG (H+L) and/or Alexa Fluor 488 goat anti-rabbit IgG
(H+L) (Invitrogen) diluted 1 : 800 in 5% BSA in PBS at 22C.
Wells were washed three times in PBS. Cover slips were
overturned onto Vectashield (Vectorlabs; Orton Southgate, UK)
mounting medium, sealed with nail varnish, and visualized on
Zeiss 710 (Cambridge, UK) on 10 or 63X. The ﬂuorescent gains
intensities and pinhole size (1 AU) were identical between
experimental samples.
Western immunoblotting
The medium was removed from the wells and cells were
incubated for 5 min in 100 lL loading buffer [56 mM sodium
dodecyl sulfate (Sigma-Aldrich), 0.05 M Tris-HCl (Bio-Rad;
Hemel Hempstead, UK) pH 6.8, 1.6 mM UltraPure EDTA
(Gibco), 6.25% glycerol (Fisher Scientiﬁc), and 0.00001% brom-
ophenol blue (Fisher Scientiﬁc)]. One unit of benzonase (Nov-
agen; EMD Millipore) supplemented with 1 lL of 1 M MgCl2
was added to each well and plates were shaken at 1500 rpm for
an additional 10 min. Samples were boiled for 1 min at 95°C then
run on 12% Bis-Tris sodium dodecyl sulfate–polyacrylamide gel
electrophoresis (SDS–PAGE) gels (Invitrogen). Migrated samples
were transferred on Immobilon-P polyvinylidene diﬂuoride mem-
branes (EMD Millipore), and then incubated for 30 min in
blotting solution (5% milk, 0.1% TWEEN 20 (Thermo Scientiﬁc)
in PBS). All primary antibodies, including rabbit polyclonal anti-
syntaxin 1b (Synaptic Systems), anti-syntaxin 1 (HPC-1, Sigma-
Aldrich), and anti-synaptobrevin 2 clone 69.1 (Synaptic Systems),
were diluted to 1 : 3000 in blotting solution and incubated for 1 h
at 22°C. Membranes were washed three times in 0.1% TWEEN
20 in PBS for 5 min and then incubated for 30 min in blotting
solution with secondary stabilized peroxidase-conjugated goat
anti-mouse and/or anti-rabbit (Thermo Scientiﬁc) at 22°C. Mem-
branes were washed three times for 5 min in 0.1% TWEEN 20 in
PBS. Bands were illuminated using SuperSignal West Dura
Extended Duration Substrate (Thermo Scientiﬁc) and signal was
visualized by autoradiogram using Fuji Medical X-Ray ﬁlms
(Ross-on-wye, UK).
Cell viability assays
Cells plated into 96-well plates (Costar; Sigma-Aldrich) exposed
to 1/10 of the amount of the transduction recipe indicated above
were incubated for 40 h. Cell Counting Kit-8 (CCK-8; Sigma-
Aldrich) was used to determine cell survival (Ishiyama et al.
1997). Assay was performed according to manufacturer’s proto-
col. Brieﬂy, 10 lL of CCK-8 solution was added to each well
and cells were incubated a further 2 h at 37°C. A Tecan Saﬁre
microplate reader (M€annerdorf, Switzerland) was used to read
absorbance at 450 nm in each well. All readings were normalized
to untreated control conditions or as otherwise indicated. Cell-free
medium with CCK-8 solution was used as a blank. BCA assay
kit (Thermo-Scientiﬁc, Cramlington, UK) was used to monitor
total protein content in each well. The medium was removed and
adherent cells were gently washed once with PBS. BCA reagent
was then added to each well-containing adherent cells, incubated
for 1 h at 37°C and the total protein content was measured at
562 nm according to the manufacturer’s protocol.
Flow cytometry
Cells treated with compounds and transfection reagents were
washed twice with PBS and resuspended in 10 mM HEPES (Fisher
Scientiﬁc), 140 mM NaCl, 2.5 mM CaCl2, pH 7.4 with 2 lg/mL
propidium iodide (PI; Sigma-Aldrich) into 12 9 75 mm round
bottom test tube (Scientiﬁc Laboratory Supplies; Wilford, UK).
After 10 min of incubation with PI, ﬂuorescent intensities of the cell
populations were measured using FACScalibur 2 (BD Bioscience).
Proper gating was determined by untreated control, and laser
intensity was determined by PI- and PI+ controls during each
experiment. Data were interpreted using FlowJo version 9.4.4 (Tree
Star Inc.; Ashland, USA).
SNARE complex reactions
GST-synaptobrevin 2 (25-84) was incubated with or without the
type D protease for 6 h at 22°C. Glutathione Sepharose 4B beads
(GE Healthcare; Little Chalfont, UK) were added and incubated
overnight at 4°C under constant rotation. Samples were washed
four times with buffer A (0.8% w/v n-octyl-b-D-glucopyranoside
(Sigma-Aldrich), 100 mM NaCl, 20 mM HEPES, pH 7.4) and
divided into two tubes. A 1 : 1 ratio of syntaxin 1A (201-245) and
SNAP25B (22-206) was added to one sample while syntaxin and
buffer A were added to the other and incubated for 3 h at 22°C.
Samples were washed four times with buffer A then heated at 95°C
for 1 min and loaded on 10% Bis-Tris SDS–PAGE gel (Invitro-
gen). For the second assay GST-SNAP25 (22-206) was added to
Glutathione Sepharose 4B beads (GE Healthcare) and incubated for
90 min at 4°C under constant rotation. Samples were washed four
times with buffer A (0.8% w/v n-octyl-b-D-glucopyranoside
(Sigma-Aldrich), 100 mM NaCl, 20 mM HEPES, pH 7.4) and
divided into four tubes. Buffer A was added to the ﬁrst sample,
FITC-synaptobrevin (31-55) was added to the second sample. A
1 : 1 ratio of FITC-syntaxin 1A (201-245) and FITC-synaptobrevin
(31-55) was added to the third sample and a 1 : 1 ratio of syntaxin
1A (1-226) and FITC-synaptobrevin (31-55) was added to the
fourth sample. Samples were incubated for 30 min at 22°C then
washed three times with buffer A, heated at 95°C for 1 min, and
loaded on 10% Bis-Tris SDS–PAGE gel (Invitrogen). ChemiDoc
XRS (Bio-Rad) was used to capture ﬂuorescent and Coomassie
images of the gels.
Statistical analysis
All experiments were performed in at least three independent
experiments. Results are presented as mean  standard deviation
(SD). Data analysis was performed using Graphpad Prism 5.0 (La
Jolla, CA, USA). The unpaired two-tailed Student’s t-test was
used for comparison. A p < 0.05 was considered statistically
signiﬁcant.
© 2013 The Authors. Journal of Neurochemistry published by John Wiley & Sons Ltd on behalf of International
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Results
Direct delivery of botulinum proteases into neuroblastoma
cells
First, we ascertained the presence of the SNARE proteins
syntaxin, SNAP25, and synaptobrevin in mouse neuroblas-
toma N2A cells by confocal microscopy. Fig. 1b shows that
the t-SNAREs (red) are located on the plasma membrane,
whereas the v-SNARE (green) is located in intracellular
vesicular pools (Bock et al. 2001; Koticha et al. 2002;
Sudhof and Rothman 2009).
Next, we explored a possibility of delivering botulinum
proteases, which cleave membrane-embedded SNAREs, into
normally resistant N2A cells. As it has been observed that
transfection reagents are capable of causing the internaliza-
tion of the Botulinum A and E proteases targeting SNAP25
(Kuo et al. 2010), we tried an array of transfection reagents to
deliver the type C and D proteases, which, respectively, target
t-SNAREs and the v-SNARE. Fig. 1c and d (upper panels)
show that Lipofectamine LTX and FuGENE HD were able to
deliver the C and D proteases into N2A cells very efﬁciently
as evidenced by changes observed in immunoblotting of the
SNARE proteins. TransPass, a bona ﬁde protein transduction
reagent, was also efﬁcient, but caused cell death as evidenced
by a reduction in total SNAP25 protein in the loading controls
at the tested dose (Fig. 1c and d upper panels). We chose to
use Lipofectamine LTX for subsequent experiments because
of its excellent tolerance by cells. Fig. 1c and d (middle
panels) show that a dose of 0.2 lg/mL of botulinum proteases
was sufﬁcient to achieve near-complete SNARE cleavage
upon 20 h incubation. This dose was used in all subsequent
experiments. Fig. 1c (bottom panel) also shows a time course
of type C protease activity, where a complete cleavage of the
syntaxin substrate can be observed even within 4 h, whereas
the SNAP25 cleavage slightly lags behind and is completed
within 8 h. We also observed a near-complete cleavage of
synaptobrevin by the D protease within 4 h (Fig. 1d, bottom
panel). Together, extensive cleavage of all three SNAREs in
Lipofectamine LTX-treated cells can be observed in the
presence of the respective botulinum proteases at 0.2 lg/mL
within 8 h.
Cytotoxic effects of the botulinum protease serotypes
C and D
It is well-known that BoNT/C has neurotoxic properties, but
botulinum effects on survival of neuroendocrine cells have
not been speciﬁcally addressed. To test cell viability of
neuroblastoma cells, we used a cell counting kit (CCK-8).
Fig. 2a (left panel) shows the normalized signals exhibited
by N2A cells following treatment with botulinum proteases.
The type C protease signiﬁcantly reduced cell viability after a
40 h exposure (*p < 0.01). Curiously, this effect was
enhanced with the addition of the type D protease, whereas
the type D protease alone was not sufﬁcient to signiﬁcantly
affect cell viability. As dehydrogenase activity might be
affected by botulinum-induced changes in membrane traf-
ﬁcking, we corroborated our observations using the BCA
protein assay which measures total protein content present in
the wells which is a direct measure of adherent cells. The
protein content of adherent cells (Fig. 2a, right panel)
precisely correlated with the CCK-8 kit results (*p < 0.01;
**p < 0.001). Lipofectamine LTX on its own did not affect
cell viability (Fig. 2a). In further experiments, we chose to
study the combined effect of type C and D proteases as
together they mediated the most potent cytotoxicity. Fig. 2b
shows a confocal image of botulinum-treated cells versus
control cells, with a substantial reduction in the number of
cells evident following the protease treatment. Next, we
tested other cell lines of neuroendocrine origin and which
carry syntaxin 1, SNAP25, and synaptobrevin 2 (Fig. 2c).
We observed a signiﬁcant cytotoxic trend in the human
neuroblastoma cell line SH-SY5Y (*p < 0.01) and substan-
tial cytotoxic effect in mouse insulinoma Min6 cells
(*p < 0.01) and neurons (*p < 0.01) compared with their
respective untreated controls (100%). The non-neuroendo-
crine human cell line Hela did not show loss of survival
which can be explained by the low levels of botulinum
proteolytic substrates in these cells.
We next investigated the time course and features of the
N2A cell demise. Fig. 3a shows that the loss in cell viability
following botulinum treatments (C and D) continues to occur
for at least 40 h. The type C protease showed a signiﬁcant
reduction in viability after 36 h (*p < 0.01), whereas the
type C and D protease displayed a signiﬁcant reduction as
early as 16 h (*p < 0.01). When observed under higher
magniﬁcation (Fig. 3b), the botulinum protease C- and D-
treated cells often displayed nuclear abnormalities, as would
be expected during programmed cell death (Danial and
Korsmeyer 2004). For ﬂow cytometry, cells with normal
morphology were gated according to the forward and side
scattering patterns using untreated cells as a control and then
total percentages of gated cells were calculated (Fig. 3c).
There was a signiﬁcant reduction (p < 0.05) in the percent-
age of morphologically normal cells in the sample cotreated
with C and D proteases. Fig. 3d shows the analysis of these
gated cells proportional to their PI labeling, a widely used
necrosis and late apoptosis marker (Lecoeur 2002). A
signiﬁcant rightward shift in PI-positive cells suggests
increased cell death of the C and D proteases-treated cells
(p < 0.01). We could not rely on the Annexin V-FITC
labeling of apoptotic cells as lipofection by itself alters lipid
balance in the plasma membrane and thus gives artiﬁcially
high Annexin V binding without affecting cell survival.
Botulinum protease-cleaved SNARE fragments mediate
cytotoxicity
As botulinum type C protease cleaves both syntaxin and
SNAP25, we next aimed to address whether cleavage of
© 2013 The Authors. Journal of Neurochemistry published by John Wiley & Sons Ltd on behalf of International
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syntaxin or SNAP25 is responsible for the cytotoxic effects
observed above. We used the BoNT/A protease, the main
ingredient of the BOTOX and Dysport preparations, which
exclusively cleaves SNAP25. Fig. 4a shows the comparative
proteolytic activity of the type A and C proteases as seen in
western immunoblotting. The major difference which can be
observed between the A and C proteases is the cleavage of
syntaxin 1. Fig. 4b shows a signiﬁcant reduction in cell
viability exclusively when the C protease is used together
with the type D protease, whereas the D protease alone or the
A and D proteases in combination exhibit no discernible
cytotoxicity. This result indicates that it is the cleavage of
syntaxin by the type C protease that is the driving force for
the observed cytotoxicity.
Finally, we tested whether transduction of type C
protease does result in production of syntaxin fragments,
as previous results (Fig. 1) indicated loss of immunoreac-
tivity. We used an antibody directed against the head
domain of syntaxin 1 (clone HPC-1) and found a clear
appearance of the syntaxin proteolytic fragment within
several hours of application of the botulinum protease at a
dose of 0.002 lg/mL (Fig. 5a).
As botulinum-cleaved syntaxin and synaptobrevin prod-
ucts are cleaved from their transmembrane anchors, they
could be soluble and may potentially form aberrant SNARE
complexes. We tested whether short SNARE fragments can
form such ternary complexes in bead pull-down assays. We
ﬁrst used GST-synaptobrevin 2 attached to beads. As can be
seen in Fig. 5b, the D protease cleaved the bead attached
GST-synaptobrevin 2 (22-84) very efﬁciently generating a
cleavage product (GST-Syb2D product) still attached to beads
through its N-terminal GST fusion. The BoNT/C protease
(a)
(b) (c)
Fig. 2 Cytotoxicity of the botulinum C and D proteases. (a) Cell
counting assay (CCK-8) was used to monitor neuroblastoma N2A cell
viability 40 h after application of the proteases in the presence or
absence of Lipofectamine LTX. Botulinum protease type C signiﬁcantly
impaired viability compared with a control condition (*p < 0.01).
Application of both proteases with Lipofectamine LTX further lowered
cell survival (**p < 0.001). Absorbance at 450 nm (AN450) normalized
to control values is proportional to cell count (left panel). The right
panel shows the absorbance at 562 nm (AN562) proportional to total
protein content in the wells as determined by the bicinchoninic acid
(BCA) assay. Botulinum protease type C in the presence of Lipofec-
tamine LTX signiﬁcantly lowered viability compared with control
condition (**p < 0.001) while the addition of the type D protease
reduced survival further (*p < 0.01). Results are presented  SD. (b)
Confocal images showing a reduction in number of N2A cells stained
with Hoechst 33342. Left panel shows cells treated with Lipofectamine
LTX alone, whereas right panel shows cells treated with C and D
proteases in the presence of Lipofectamine LTX. White bar: 100 lm.
(c) CCK-8 assay was used to monitor viability of the indicated cells
following the addition of Lipofectamine LTX with or without botulinum
proteases. Control conditions where cells were treated with Lipofec-
tamine LTX alone are shown as white columns. Results were
normalized to control (LTX alone,  SD). A signiﬁcant (**p < 0.001)
loss of viability compared with untreated controls was observed in
N2A, SH-SY5Y, Min6, and rat brain cortical cells, which comprise both
neurons and non-neuronal cells (*p < 0.01).
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produces the syntaxin 1-253 aa fragment which encompasses
the short syntaxin peptide 201-245 (Ferrari et al. 2012).
Fig. 5b also shows that GST-synaptobrevin, cleaved or not,
was able to pull-down both SNAP25 and the short syntaxin
fragment. This suggests that botulinum protease C- and D-
released products can still interact to form ternary SNARE
complexes. Furthermore, we used GST-SNAP25 bound to
beads to investigate SNARE interactions with truncated
syntaxin 1-226 and a minimal synaptobrevin further reduced
to only 25 amino acids. Fig. 5c shows that the short
synaptobrevin and syntaxin fragments, with or without the
syntaxin regulatory head domain, can still form SNARE
complexes evidenced in the pull-down reactions.
To investigate whether shortened SNARE fragments can
trigger cytotoxicity, we treated the N2A cells with syntaxin 1
(201-245, 5 lg/mL) and/or synaptobrevin 2 (25-52, 5 lg/
mL) peptides, with or without Lipofectamine LTX. Com-
plexin, a SNARE protein that does not directly contribute to
the tetrahelical bundle was used as control. Penetratin, a cell-
penetrating peptide, was also used as a negative control to
eliminate the possibility that non-speciﬁc internalization
might contribute to cytotoxicity. Fig. 5d shows that N2A
cells treated with the shortened SNARE peptides exhibited
decreased cell survival compared with control conditions.
The syntaxin fragment alone was very efﬁcient even at low
concentrations (Fig. 5d and e), thereby masking possible
cumulative effects. No decrease in viability was observed
with the same concentrations of complexin or penetratin
demonstrating the importance of the SNARE ternary inter-
actions involving syntaxin as the major driving factor in
triggering cytotoxicity.
Discussion
Botulinum neurotoxins have been invaluable in the studies of
the SNARE machinery. Here, we demonstrate a straightfor-
ward and easy method to deliver botulinum type D and C
proteases into normally refractory cells to cleave membrane-
embedded v- and t-SNAREs. Our results expand upon
previous observations of the delivery of SNAP25 proteases
type A and E (Kuo et al. 2010). A number of studies
highlighted BoNT/C cytotoxic effects on central and periph-
eral neurons, (Foran et al. 2003; Berliocchi et al. 2005; Zhao
et al. 2010; Peng et al. 2013), but possible cytotoxic effects
in normally resistant neuroendocrine cells have not been
addressed. Our newly discovered ability to introduce botu-
linum proteases in all cultured cells suddenly revealed
cytotoxic effects especially for the type C botulinum
protease. We observed increase in nuclear PI labeling and
nuclear abnormalities following botulinum type C and D
protease application which correspond to necrosis and late
apoptosis, respectively. This is consistent with the observed
caspase 3 activation and apoptosis of cerebellar neurons upon
BoNT/C administration (Berliocchi et al. 2005). Our data
(a) (b)
(c) (d)
Fig. 3 Time course of botulinum-triggered
cytotoxic effects. (a) A late onset of toxicity
observed following application of type C, type D,
and C and D proteases. A signiﬁcant (*p < 0.01)
reduction in cell viability is observed at 16 h post-
transduction for the combined C and D protease,
whereas a signiﬁcant (*p < 0.01) reduction in the
type C protease-treated cells can be observed
after 40 h. Results are presented  SD. (b)
Confocal image showing fragmented nuclei of
N2A cells treated with the C and D proteases,
indicating apoptosis. White bar: 20 lm. (c)
Histogram of the forward scatter height (FSC-H)
observed by ﬂow cytometry. The gated region on
the right contained morphologically normal (i.e.,
size and complexity) cells, whereas the left section
shows the cell debris. Botulinum protease-treated
cells (red) exhibit higher debris count compared
with control (gray) (p < 0.05). (d) Histogram
representation of FL-H (ﬂuorescent height) signal
of the propidium iodide (PI)-stainedmorphologically
normal cells indicates a signiﬁcant increase in cell
death following application of botulinum proteases
(p < 0.01).
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show that botulinum protease-induced cell death can occur
independent of axonal changes.
The precise mechanisms of botulinum cytotoxicity in
neurons are not fully understood. As one possible mechanism
which warrants further investigations, we propose that
botulinum cleavage products that still contain SNARE
interacting domains are able to compete with normal SNARE
interplay and disrupt functionally important trafﬁcking and
vesicular fusion events. Our results showing synergistic
effects of botulinum proteases on cytotoxicity of non-
neuronal cells, as well ternary complex formation by
shortened SNARE peptides, suggest that cellular well-being
generally relies on proper SNARE localization and precisely
regulated stoichiometry of SNARE interactions. Although a
recent study suggested that the general presence of neuronal
SNARE proteins is important for neuronal survival, this can
be explained by the importance of intercellular signaling for
the maintenance of neuronal circuitry (Peng et al. 2013).
Similarly, it could be argued that cell–cell communication is
important for cancer cell survival. However, it is well-known
that cancer neuroendocrine cells sometimes lose secretory
pathway components and yet they are able to grow and
proliferate in a normal way (Pance et al. 2006). As
botulinum-released SNARE fragments can form ternary
complexes they may contribute to deregulation of precise
membrane trafﬁcking necessary for correct cell function
(D’Alessandro and Meldolesi 2013).
Whereas botulinum type C protease possesses the most
potent cytotoxic effects, our data show that it is speciﬁcally
cleavage of syntaxin rather than SNAP25 which mediates
cell toxicity. Indeed, when we tested the type A protease,
which only cleaves SNAP25, no cytotoxic effects were
observed. A previous study suggested that BoNT/C-cleaved
syntaxin degrades too quickly to interfere with intracellular
functions, but this inference was based on loss of immuno-
reactivity (Foran et al. 2003). When we probed neuroblas-
toma cells using a well-known syntaxin 1 antibody we
observed a persistent accumulation of the syntaxin fragment
triggered by the type C protease treatment which is in accord
with a previous study (Tsukamoto et al. 2012); evidently the
fragments are not completely degraded and may take part in
aberrant SNARE interactions. We now show that syntaxin
fragments, as short as 45 aa, can drive SNARE complex
formation as evidenced by pull-downs with SNAP25 and
synaptobrevin, even if the latter cleaved by the botulinum
type D protease.
This study raises several questions for future investiga-
tions. The mechanism of Lipofectamine LTX-induced trans-
duction of botulinum enzymes and small peptides remains
unclear because of proprietary reasons and the active
ingredients should be understood considering that this
reagent was more effective than bona ﬁde protein transduc-
tion preparations. It is also not clear, why generation of
syntaxin fragments is more cytotoxic compared with syna-
ptobrevin despite that in both cases botulinum proteases
sever the SNARE membrane-embedded parts (Peng et al.
2013). It will be revealing to detect even smaller SNARE
degradation products following botulinum treatment as small
syntaxin and synaptobrevin fragments can still form irre-
versible SNARE complexes (Ferrari et al. 2012). This is also
important in view of SNARE degradation and deregulation
which apparently takes place in neurodegenerative disorders
(Garcia-Reitbock et al. 2010). The importance of normal
SNARE function was previously suggested by a genetic
study where deletion of synaptic vesicle protein cystein
string protein a, a SNARE chaperon, led to massive
neurodegeneration in vivo (Sharma et al. 2011).
Our results have implications for the use of BoNT/C in
biomedical applications and further validate the safer cyto-
logical characteristics of BoNT/A-based preparations such as
BOTOX and Dysport. BoNT proteases are currently of high
pharmaceutical interest (Chaddock and Marks 2006; Chen
and Barbieri 2009; Foster and Chaddock 2010; Davletov
et al. 2012; Ferrari et al. 2013; Naumann et al. 2013) and
the newly highlighted delivery mechanisms could greatly
advance the ongoing botulinum research. Considering the
observed cytotoxicity, the botulinum proteases could be
utilized as molecular surgery tools for neuroendocrine cancer
(a)
(b)
Fig. 4 The importance of syntaxin cleavage in botulinum-triggered cell
demise. (a) Immunoblot showing that, in the presence of Lipofectamine
LTX, the botulinum protease type C cleaves both syntaxin 1 and
SNAP25 in N2A cells, whereas the type A protease cleaves SNAP25
only. Type C protease removes the last eight residues of SNAP25
(SNAP25Δ8), whereas type A removes the last nine (SNAP25Δ9). (b)
The bar chart showing N2A cell demise following a 40 h treatment with
the indicated proteases. Type A-induced cleavage of SNAP25, even in
the presence of the type D protease, is insufﬁcient to drive the cytotoxic
effects. In contrast, cleavage of syntaxin by type C protease has a
strong effect on cell survival (**p < 0.001). Results are normalized to
control and presented  SD.
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therapies. Targeted delivery of botulinum proteases could
even be combined with short syntaxin peptides for cumula-
tive cytotoxic effects. Many neuroendocrine tumors give rise
to complicated endocrinopathies that require constant mon-
itoring and problematic surgical interventions (Bangaru et al.
2010; Batcher et al. 2011). The possibility of using certain
botulinum proteases/SNARE peptides to destroy cancerous
neuroendocrine cells paves the way for devising strategies to
both block the pathological release of hormones and
concomitantly halt tumor proliferation.
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